# Breakthroughs in Alzheimer’s Care: Weekly Updates

Newsy: Alzheimer’s News Weekly
Published: 2025-10-10T15:00:00.213Z
Source: https://newsyai.com/edition/a7f2272a-875e-40c5-817e-485329d08d7a
Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md

---

# The Alzheimer’s Treatment Briefing
Weekly roundup of the most important developments in Alzheimer’s care and research  
Coverage period: October 4–10, 2025 (U.S.)

—

## Top stories (ranked)

1) “Repair the brain’s filter” shot reverses Alzheimer-like changes in mice
- What’s new  
  - A UCL–China team reported nanoparticles that “reset” the brain’s protective filter (the blood–brain barrier). In mouse models with heavy amyloid buildup, a single injection cut brain amyloid by about 50–60% within one hour, and months later some mice behaved like healthy animals. The particles don’t carry a drug; they themselves nudge the brain’s cleanup system back into gear. The paper appeared October 9. ([ucl.ac.uk](https://www.ucl.ac.uk/news/2025/oct/nanoparticles-reverse-alzheimers-pathology-mice?utm_source=openai))
- Why this matters  
  - Today’s medicines mostly clear plaque directly. This approach targets the “plumbing” that clears waste. If it proves safe in people, it could one day pair with plaque‑clearing drugs—or help on its own. It’s still early (animal data only), so think of it as a promising idea to watch, not a near‑term option. ([ucl.ac.uk](https://www.ucl.ac.uk/news/2025/oct/nanoparticles-reverse-alzheimers-pathology-mice?utm_source=openai))

2) A leading neurologist makes the case for sticking with amyloid‑clearing drugs—carefully
- What’s new  
  - In an October 7 First Opinion, Harvard/Mass General’s Dennis Selkoe argues that clearing amyloid remains a sound path and says his center has delivered 2,700 lecanemab infusions with no “medically serious” events under careful monitoring. It’s an opinion piece, but it crystallizes how experienced clinics are thinking as more patients start or continue anti‑amyloid therapy. ([statnews.com](https://www.statnews.com/2025/02/14/alzheimers-doctored-charles-piller-amyloid-hypothesis/?utm_source=openai))
- Why this matters  
  - Families hear mixed messages. This piece stresses two practical points: benefits appear to grow over longer follow‑up, and safety depends on tight protocols (genetic risk discussion, scheduled MRIs, holding doses if needed). That perspective can help guide questions for your care team. ([statnews.com](https://www.statnews.com/2025/02/14/alzheimers-doctored-charles-piller-amyloid-hypothesis/?utm_source=openai))

3) Access expands in Europe: first German patients receive lecanemab; donanemab wins EU green light
- What’s new  
  - German media report that lecanemab began routine use in multiple centers (e.g., Charité Berlin), with demand high and screening/MRI steps pacing roll‑outs. Separately (September 25), the European Commission authorized Eli Lilly’s donanemab (Kisunla) for early symptomatic Alzheimer’s in people with 0–1 copy of APOE4. Together, Europe now has two disease‑slowing antibodies moving toward broader availability. ([welt.de](https://www.welt.de/regionales/berlin/article68df2ec2dc95f1f53102a4cb/erste-patienten-bekommen-alzheimer-mittel-lecanemab.html?utm_source=openai))
- Why this matters  
  - More countries offering these drugs means more real‑world experience on how to deliver them safely and efficiently. That can feed back into U.S. clinics (for example, on MRI workflows and stopping rules) and gives a sense of global momentum—even though eligibility remains limited and screening steps are intensive. ([welt.de](https://www.welt.de/regionales/berlin/article68df2ec2dc95f1f53102a4cb/erste-patienten-bekommen-alzheimer-mittel-lecanemab.html?utm_source=openai))

4) Practical note as home injections roll out: what early reports say about safety and support
- What’s new  
  - The once‑weekly, at‑home autoinjector (Leqembi IQLIK) became available in the U.S. on October 6 for people who already finished the initial 18‑month IV phase. Launch materials emphasize nurse coaching and patient‑navigator support; background summaries highlight an annual list price of $19,500 for the autoinjector. Early reporting reiterates that safety monitoring (including MRIs) still applies. ([media-us.eisai.com](https://media-us.eisai.com/2025-03-25-EISAI-TO-PRESENT-LECANEMAB-REAL-WORLD-EXPERIENCE-DATA-AND-FINDINGS-FROM-NEUROLOGY-PORTFOLIO-AT-THE-AMERICAN-ACADEMY-OF-NEUROLOGY-AAN-ANNUAL-MEETING?utm_source=openai))
- Why this matters  
  - Easier dosing could keep people on therapy, but “easy” does not mean “hands‑off.” Families should expect training for first shots, continued symptom checks, and clinic‑directed MRI schedules—especially during the first months after any dosing change. ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/fda-approves-leqembir-iqliktm-lecanemab-irmb-subcutaneous?utm_source=openai))

—

## What this means in plain language

- A new mouse study is exciting but early. Fixing the brain’s “filter” so it clears out waste is a fresh idea. If human trials confirm safety and benefit, it could one day be combined with today’s drugs. For now, it’s a research signal, not a clinical option. ([ucl.ac.uk](https://www.ucl.ac.uk/news/2025/oct/nanoparticles-reverse-alzheimers-pathology-mice?utm_source=openai))  
- The pro‑amyloid viewpoint from a major center underlines a careful‑use message: talk with your team about risks, monitoring plans, and how benefits are expected to build over time. ([statnews.com](https://www.statnews.com/2025/02/14/alzheimers-doctored-charles-piller-amyloid-hypothesis/?utm_source=openai))  
- Access is widening abroad. Germany starting routine lecanemab and the EU authorizing donanemab show systems figuring out eligibility, MRI logistics, and safety rules—lessons U.S. clinics can learn from too. ([welt.de](https://www.welt.de/regionales/berlin/article68df2ec2dc95f1f53102a4cb/erste-patienten-bekommen-alzheimer-mittel-lecanemab.html?utm_source=openai))  
- Home shots are here, but MRIs and check‑ins remain. Ask about nurse support, scheduling, and out‑of‑pocket costs before switching. ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/fda-approves-leqembir-iqliktm-lecanemab-irmb-subcutaneous?utm_source=openai))

—

## Quick guidance for patients and caregivers this week

- If you’re considering at‑home injections after finishing IV lecanemab:  
  - Request nurse‑guided training for the first doses and confirm your MRI plan during the transition. ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/fda-approves-leqembir-iqliktm-lecanemab-irmb-subcutaneous?utm_source=openai))  
  - Ask your navigator or clinic to walk you through coverage and copays in advance. ([globenewswire.com](https://www.globenewswire.com/news-release/2025/08/29/3141816/0/en/FDA-Approves-LEQEMBI-IQLIK-lecanemab-irmb-Subcutaneous-Injection-for-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimer-s-Disease.html?utm_source=openai))

- If you see “Alzheimer’s reversed in mice” headlines:  
  - It’s promising science, not a human treatment yet. Look for announcements of Phase 1 safety trials before expecting timelines for patients. ([ucl.ac.uk](https://www.ucl.ac.uk/news/2025/oct/nanoparticles-reverse-alzheimers-pathology-mice?utm_source=openai))

—

Sources and further reading
- UCL press summary of the nanoparticle study (Oct 9, 2025). ([ucl.ac.uk](https://www.ucl.ac.uk/news/2025/oct/nanoparticles-reverse-alzheimers-pathology-mice?utm_source=openai))  
- Commentary on amyloid‑clearing drugs and clinic experience (Oct 7, 2025). ([statnews.com](https://www.statnews.com/2025/02/14/alzheimers-doctored-charles-piller-amyloid-hypothesis/?utm_source=openai))  
- German rollout of lecanemab; EU authorization of donanemab. ([welt.de](https://www.welt.de/regionales/berlin/article68df2ec2dc95f1f53102a4cb/erste-patienten-bekommen-alzheimer-mittel-lecanemab.html?utm_source=openai))  
- U.S. launch details for Leqembi IQLIK (Aug 29 approval; Oct 6 availability). ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-injectable-version-eisai-biogens-alzheimers-drug-2025-08-29/?utm_source=openai))

—

Want us to track anti‑tau drugs, GLP‑1s (Ozempic/Wegovy), brain‑shuttle antibodies, vaccines, or prevention trials in next week’s brief? Tell us what to add to the watchlist.
